Expleo Solutions Limited (EXPLEOSOL.BO) Stock Competitors & Peer Comparison

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, TCS.NS has a market cap of 7.8T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while TCS.NS trades at ₹2,161.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas TCS.NS's P/E ratio is 15.90. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TCS.NS's ROE of +0.46%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TCS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TCS.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, TCS.BO has a market cap of 7.8T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while TCS.BO trades at ₹2,161.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas TCS.BO's P/E ratio is 15.90. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TCS.BO's ROE of +0.46%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TCS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TCS.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, INFY.NS has a market cap of 4.5T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while INFY.NS trades at ₹1,116.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas INFY.NS's P/E ratio is 14.69. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INFY.NS's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to INFY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INFY.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, INFY.BO has a market cap of 4.5T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while INFY.BO trades at ₹1,116.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas INFY.BO's P/E ratio is 16.01. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INFY.BO's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to INFY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INFY.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, HCLTECH.NS has a market cap of 3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while HCLTECH.NS trades at ₹1,109.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas HCLTECH.NS's P/E ratio is 18.08. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HCLTECH.NS's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HCLTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HCLTECH.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, HCLTECH.BO has a market cap of 3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while HCLTECH.BO trades at ₹1,109.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas HCLTECH.BO's P/E ratio is 18.08. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HCLTECH.BO's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HCLTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HCLTECH.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, WIPRO.NS has a market cap of 1.9T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while WIPRO.NS trades at ₹180.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas WIPRO.NS's P/E ratio is 14.34. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to WIPRO.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to WIPRO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check WIPRO.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, WIPRO.BO has a market cap of 1.9T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while WIPRO.BO trades at ₹180.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas WIPRO.BO's P/E ratio is 14.47. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to WIPRO.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to WIPRO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check WIPRO.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, LTIM.NS has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while LTIM.NS trades at ₹4,535.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas LTIM.NS's P/E ratio is 28.28. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTIM.NS's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to LTIM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTIM.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, TECHM.NS has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while TECHM.NS trades at ₹1,429.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas TECHM.NS's P/E ratio is 26.40. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TECHM.NS's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TECHM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TECHM.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, TECHM.BO has a market cap of 1.3T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while TECHM.BO trades at ₹1,429.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas TECHM.BO's P/E ratio is 27.41. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TECHM.BO's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to TECHM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TECHM.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, LTIM.BO has a market cap of 1.1T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while LTIM.BO trades at ₹3,855.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas LTIM.BO's P/E ratio is 24.06. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTIM.BO's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to LTIM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTIM.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, LTM.NS has a market cap of 1.1T. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while LTM.NS trades at ₹3,844.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas LTM.NS's P/E ratio is 22.72. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTM.NS's ROE of +0.21%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to LTM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTM.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, PERSISTENT.NS has a market cap of 751.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while PERSISTENT.NS trades at ₹4,811.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas PERSISTENT.NS's P/E ratio is 40.51. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PERSISTENT.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to PERSISTENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PERSISTENT.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, PERSISTENT.BO has a market cap of 751.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while PERSISTENT.BO trades at ₹4,810.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas PERSISTENT.BO's P/E ratio is 43.44. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PERSISTENT.BO's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to PERSISTENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PERSISTENT.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, COFORGE.BO has a market cap of 459.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while COFORGE.BO trades at ₹1,367.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas COFORGE.BO's P/E ratio is 31.16. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to COFORGE.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to COFORGE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check COFORGE.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, COFORGE.NS has a market cap of 459.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while COFORGE.NS trades at ₹1,367.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas COFORGE.NS's P/E ratio is 31.24. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to COFORGE.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to COFORGE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check COFORGE.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, MPHASIS.NS has a market cap of 433.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while MPHASIS.NS trades at ₹2,270.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas MPHASIS.NS's P/E ratio is 24.07. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MPHASIS.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MPHASIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MPHASIS.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, MPHASIS.BO has a market cap of 433.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while MPHASIS.BO trades at ₹2,270.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas MPHASIS.BO's P/E ratio is 24.08. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MPHASIS.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MPHASIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MPHASIS.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, LTTS.NS has a market cap of 355.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while LTTS.NS trades at ₹3,351.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas LTTS.NS's P/E ratio is 28.94. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTTS.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to LTTS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTTS.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, LTTS.BO has a market cap of 355.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while LTTS.BO trades at ₹3,349.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas LTTS.BO's P/E ratio is 28.97. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to LTTS.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to LTTS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check LTTS.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, TATATECH.BO has a market cap of 309.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while TATATECH.BO trades at ₹760.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas TATATECH.BO's P/E ratio is 56.61. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TATATECH.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TATATECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TATATECH.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, TATATECH.NS has a market cap of 309B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while TATATECH.NS trades at ₹761.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas TATATECH.NS's P/E ratio is 56.54. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TATATECH.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TATATECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TATATECH.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, HEXT.NS has a market cap of 303.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while HEXT.NS trades at ₹498.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas HEXT.NS's P/E ratio is 22.07. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HEXT.NS's ROE of +0.23%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to HEXT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HEXT.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, KPITTECH.BO has a market cap of 203.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while KPITTECH.BO trades at ₹750.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas KPITTECH.BO's P/E ratio is 32.22. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to KPITTECH.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to KPITTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check KPITTECH.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, KPITTECH.NS has a market cap of 203.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while KPITTECH.NS trades at ₹749.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas KPITTECH.NS's P/E ratio is 32.16. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to KPITTECH.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to KPITTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check KPITTECH.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, REDINGTON.NS has a market cap of 184.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while REDINGTON.NS trades at ₹236.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas REDINGTON.NS's P/E ratio is 12.39. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to REDINGTON.NS's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to REDINGTON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check REDINGTON.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, REDINGTON.BO has a market cap of 184.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while REDINGTON.BO trades at ₹236.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas REDINGTON.BO's P/E ratio is 12.42. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to REDINGTON.BO's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to REDINGTON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check REDINGTON.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, FSL.BO has a market cap of 172B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while FSL.BO trades at ₹247.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas FSL.BO's P/E ratio is 25.88. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to FSL.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to FSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check FSL.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, FSL.NS has a market cap of 170.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while FSL.NS trades at ₹247.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas FSL.NS's P/E ratio is 25.89. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to FSL.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to FSL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check FSL.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, HEXAWARE.NS has a market cap of 141.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while HEXAWARE.NS trades at ₹470.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas HEXAWARE.NS's P/E ratio is 22.98. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HEXAWARE.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HEXAWARE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HEXAWARE.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ECLERX.NS has a market cap of 130.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ECLERX.NS trades at ₹1,396.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ECLERX.NS's P/E ratio is 18.76. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ECLERX.NS's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ECLERX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ECLERX.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ECLERX.BO has a market cap of 130B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ECLERX.BO trades at ₹1,395.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ECLERX.BO's P/E ratio is 18.74. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ECLERX.BO's ROE of +0.29%. Regarding short-term risk, EXPLEOSOL.BO and ECLERX.BO have similar daily volatility (4.03).Check ECLERX.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ZENSARTECH.NS has a market cap of 102.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ZENSARTECH.NS trades at ₹452.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ZENSARTECH.NS's P/E ratio is 13.44. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ZENSARTECH.NS's ROE of +0.18%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ZENSARTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ZENSARTECH.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ZENSARTECH.BO has a market cap of 102.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ZENSARTECH.BO trades at ₹452.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ZENSARTECH.BO's P/E ratio is 14.05. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ZENSARTECH.BO's ROE of +0.18%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ZENSARTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ZENSARTECH.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, BSOFT.BO has a market cap of 88.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while BSOFT.BO trades at ₹316.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas BSOFT.BO's P/E ratio is 17.09. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to BSOFT.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to BSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check BSOFT.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, BSOFT.NS has a market cap of 88.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while BSOFT.NS trades at ₹316.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas BSOFT.NS's P/E ratio is 17.09. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to BSOFT.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to BSOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check BSOFT.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, SONATSOFTW.NS has a market cap of 70.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while SONATSOFTW.NS trades at ₹254.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas SONATSOFTW.NS's P/E ratio is 15.19. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SONATSOFTW.NS's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SONATSOFTW.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SONATSOFTW.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, SONATSOFTW.BO has a market cap of 70.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while SONATSOFTW.BO trades at ₹253.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas SONATSOFTW.BO's P/E ratio is 15.16. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SONATSOFTW.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SONATSOFTW.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SONATSOFTW.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, RSYSTEMINT.BO has a market cap of 63.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while RSYSTEMINT.BO trades at ₹531.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas RSYSTEMINT.BO's P/E ratio is 106.05. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RSYSTEMINT.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to RSYSTEMINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMINT.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, HAPPSTMNDS.NS has a market cap of 52.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while HAPPSTMNDS.NS trades at ₹349.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas HAPPSTMNDS.NS's P/E ratio is 24.84. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HAPPSTMNDS.NS's ROE of +0.13%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HAPPSTMNDS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HAPPSTMNDS.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, HAPPSTMNDS.BO has a market cap of 52.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while HAPPSTMNDS.BO trades at ₹349.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas HAPPSTMNDS.BO's P/E ratio is 24.78. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to HAPPSTMNDS.BO's ROE of +0.13%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to HAPPSTMNDS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check HAPPSTMNDS.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, MASTEK.NS has a market cap of 48.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while MASTEK.NS trades at ₹1,577.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas MASTEK.NS's P/E ratio is 12.18. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MASTEK.NS's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MASTEK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MASTEK.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, MASTEK.BO has a market cap of 48.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while MASTEK.BO trades at ₹1,577.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas MASTEK.BO's P/E ratio is 12.18. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MASTEK.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MASTEK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MASTEK.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, DATAMATICS.BO has a market cap of 46.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while DATAMATICS.BO trades at ₹779.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas DATAMATICS.BO's P/E ratio is 23.69. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DATAMATICS.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to DATAMATICS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DATAMATICS.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, DATAMATICS.NS has a market cap of 46B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while DATAMATICS.NS trades at ₹778.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas DATAMATICS.NS's P/E ratio is 23.70. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DATAMATICS.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to DATAMATICS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DATAMATICS.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ASMTEC.BO has a market cap of 41B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ASMTEC.BO trades at ₹3,452.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ASMTEC.BO's P/E ratio is 83.05. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ASMTEC.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ASMTEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ASMTEC.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, CAMS.NS has a market cap of 37.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while CAMS.NS trades at ₹757.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas CAMS.NS's P/E ratio is 39.62. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CAMS.NS's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CAMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CAMS.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, CAMS.BO has a market cap of 37.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while CAMS.BO trades at ₹757.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas CAMS.BO's P/E ratio is 39.68. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CAMS.BO's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CAMS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CAMS.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, CIGNITITEC.BO has a market cap of 34.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while CIGNITITEC.BO trades at ₹1,265.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas CIGNITITEC.BO's P/E ratio is 11.58. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CIGNITITEC.BO's ROE of +0.31%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CIGNITITEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CIGNITITEC.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, CIGNITITEC.NS has a market cap of 34.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while CIGNITITEC.NS trades at ₹1,260.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas CIGNITITEC.NS's P/E ratio is 11.53. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CIGNITITEC.NS's ROE of +0.31%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to CIGNITITEC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CIGNITITEC.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, SASKEN.NS has a market cap of 32.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while SASKEN.NS trades at ₹2,120.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas SASKEN.NS's P/E ratio is 59.82. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SASKEN.NS's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to SASKEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SASKEN.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, SASKEN.BO has a market cap of 32.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while SASKEN.BO trades at ₹2,118.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas SASKEN.BO's P/E ratio is 59.90. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SASKEN.BO's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SASKEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SASKEN.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, RSYSTEMS.BO has a market cap of 29.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while RSYSTEMS.BO trades at ₹251.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas RSYSTEMS.BO's P/E ratio is 16.86. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RSYSTEMS.BO's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to RSYSTEMS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMS.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, RSYSTEMS.NS has a market cap of 29.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while RSYSTEMS.NS trades at ₹251.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas RSYSTEMS.NS's P/E ratio is 14.62. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RSYSTEMS.NS's ROE of +0.26%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to RSYSTEMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RSYSTEMS.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, RPSGVENT.NS has a market cap of 28.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while RPSGVENT.NS trades at ₹872.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas RPSGVENT.NS's P/E ratio is -20.93. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RPSGVENT.NS's ROE of -0.04%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to RPSGVENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RPSGVENT.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, RPSGVENT.BO has a market cap of 28.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while RPSGVENT.BO trades at ₹872.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas RPSGVENT.BO's P/E ratio is -20.91. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to RPSGVENT.BO's ROE of -0.04%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to RPSGVENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check RPSGVENT.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, PROTEAN.NS has a market cap of 25.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while PROTEAN.NS trades at ₹617.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas PROTEAN.NS's P/E ratio is 25.02. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PROTEAN.NS's ROE of +0.10%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to PROTEAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PROTEAN.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, PROTEAN.BO has a market cap of 25.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while PROTEAN.BO trades at ₹617.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas PROTEAN.BO's P/E ratio is 24.98. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to PROTEAN.BO's ROE of +0.10%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to PROTEAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check PROTEAN.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, SAKSOFT.BO has a market cap of 17.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while SAKSOFT.BO trades at ₹138.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas SAKSOFT.BO's P/E ratio is 14.67. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SAKSOFT.BO's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to SAKSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SAKSOFT.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, SAKSOFT.NS has a market cap of 17.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while SAKSOFT.NS trades at ₹137.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas SAKSOFT.NS's P/E ratio is 13.53. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SAKSOFT.NS's ROE of +0.20%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SAKSOFT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SAKSOFT.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ACCELYA.BO has a market cap of 16.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ACCELYA.BO trades at ₹1,120.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ACCELYA.BO's P/E ratio is 15.53. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ACCELYA.BO's ROE of +0.35%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ACCELYA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ACCELYA.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ACCELYA.NS has a market cap of 16.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ACCELYA.NS trades at ₹1,117.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ACCELYA.NS's P/E ratio is 15.49. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ACCELYA.NS's ROE of +0.35%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ACCELYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ACCELYA.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, DSSL.BO has a market cap of 16.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while DSSL.BO trades at ₹1,285.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas DSSL.BO's P/E ratio is 19.28. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DSSL.BO's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DSSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DSSL.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, DSSL.NS has a market cap of 16.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while DSSL.NS trades at ₹1,284.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas DSSL.NS's P/E ratio is 19.26. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DSSL.NS's ROE of +0.32%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DSSL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DSSL.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, MMWL.BO has a market cap of 14.5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while MMWL.BO trades at ₹12.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas MMWL.BO's P/E ratio is 256.40. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MMWL.BO's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MMWL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MMWL.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, AURUM.NS has a market cap of 14B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while AURUM.NS trades at ₹183.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas AURUM.NS's P/E ratio is 733.56. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to AURUM.NS's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to AURUM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check AURUM.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, AURUM.BO has a market cap of 14B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while AURUM.BO trades at ₹182.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas AURUM.BO's P/E ratio is 730.60. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to AURUM.BO's ROE of +0.00%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to AURUM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check AURUM.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, MCLOUD.NS has a market cap of 13.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while MCLOUD.NS trades at ₹22.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas MCLOUD.NS's P/E ratio is 12.63. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MCLOUD.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MCLOUD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MCLOUD.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, MCLOUD.BO has a market cap of 13B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while MCLOUD.BO trades at ₹22.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas MCLOUD.BO's P/E ratio is 12.56. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MCLOUD.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MCLOUD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MCLOUD.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, NINSYS.NS has a market cap of 12.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while NINSYS.NS trades at ₹697.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas NINSYS.NS's P/E ratio is 40.43. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to NINSYS.NS's ROE of +0.42%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to NINSYS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check NINSYS.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, NINSYS.BO has a market cap of 12.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while NINSYS.BO trades at ₹689.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas NINSYS.BO's P/E ratio is 39.99. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to NINSYS.BO's ROE of +0.44%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to NINSYS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check NINSYS.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, EXPLEOSOL.NS has a market cap of 12.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while EXPLEOSOL.NS trades at ₹784.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas EXPLEOSOL.NS's P/E ratio is 9.82. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to EXPLEOSOL.NS's ROE of +0.17%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to EXPLEOSOL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check EXPLEOSOL.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ORIENTTECH.NS has a market cap of 11.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ORIENTTECH.NS trades at ₹252.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ORIENTTECH.NS's P/E ratio is 254.00. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ORIENTTECH.NS's ROE of +0.01%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ORIENTTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ORIENTTECH.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, BGDL.BO has a market cap of 10.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while BGDL.BO trades at ₹102.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas BGDL.BO's P/E ratio is -10200.00. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to BGDL.BO's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to BGDL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check BGDL.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, 3IINFOTECH.BO has a market cap of 9.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while 3IINFOTECH.BO trades at ₹54.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas 3IINFOTECH.BO's P/E ratio is 111.67. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to 3IINFOTECH.BO's ROE of +0.15%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to 3IINFOTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check 3IINFOTECH.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, XCHANGING.BO has a market cap of 7.1B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while XCHANGING.BO trades at ₹63.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas XCHANGING.BO's P/E ratio is 11.82. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to XCHANGING.BO's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to XCHANGING.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XCHANGING.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, XCHANGING.NS has a market cap of 7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while XCHANGING.NS trades at ₹63.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas XCHANGING.NS's P/E ratio is 11.80. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to XCHANGING.NS's ROE of +0.16%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to XCHANGING.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XCHANGING.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, VAKRANGEE.NS has a market cap of 6.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while VAKRANGEE.NS trades at ₹6.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas VAKRANGEE.NS's P/E ratio is 61.90. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to VAKRANGEE.NS's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to VAKRANGEE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check VAKRANGEE.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, VAKRANGEE.BO has a market cap of 6.7B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while VAKRANGEE.BO trades at ₹6.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas VAKRANGEE.BO's P/E ratio is 62.00. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to VAKRANGEE.BO's ROE of +0.05%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to VAKRANGEE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check VAKRANGEE.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ADSL.NS has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ADSL.NS trades at ₹117.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ADSL.NS's P/E ratio is 18.79. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ADSL.NS's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ADSL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ADSL.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, MINDTECK.NS has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while MINDTECK.NS trades at ₹207.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas MINDTECK.NS's P/E ratio is 21.11. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MINDTECK.NS's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to MINDTECK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MINDTECK.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ADSL.BO has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ADSL.BO trades at ₹117.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ADSL.BO's P/E ratio is 18.73. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ADSL.BO's ROE of +0.06%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ADSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ADSL.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, MINDTECK.BO has a market cap of 6.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while MINDTECK.BO trades at ₹205.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas MINDTECK.BO's P/E ratio is 20.83. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to MINDTECK.BO's ROE of +0.11%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to MINDTECK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check MINDTECK.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ONWARDTEC.NS has a market cap of 5.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ONWARDTEC.NS trades at ₹248.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ONWARDTEC.NS's P/E ratio is 12.71. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ONWARDTEC.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to ONWARDTEC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ONWARDTEC.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, ONWARDTEC.BO has a market cap of 5.6B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while ONWARDTEC.BO trades at ₹247.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas ONWARDTEC.BO's P/E ratio is 12.69. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to ONWARDTEC.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to ONWARDTEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check ONWARDTEC.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, TERASOFT.NS has a market cap of 5.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while TERASOFT.NS trades at ₹424.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas TERASOFT.NS's P/E ratio is 21.38. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TERASOFT.NS's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to TERASOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TERASOFT.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, TERASOFT.BO has a market cap of 5.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while TERASOFT.BO trades at ₹422.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas TERASOFT.BO's P/E ratio is 21.35. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to TERASOFT.BO's ROE of +0.19%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to TERASOFT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check TERASOFT.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, SILVERTUC.BO has a market cap of 5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while SILVERTUC.BO trades at ₹198.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas SILVERTUC.BO's P/E ratio is 70.30. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SILVERTUC.BO's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SILVERTUC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SILVERTUC.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, SILVERTUC.NS has a market cap of 5B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while SILVERTUC.NS trades at ₹198.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas SILVERTUC.NS's P/E ratio is 70.24. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SILVERTUC.NS's ROE of +0.25%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to SILVERTUC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SILVERTUC.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, DIGISPICE.NS has a market cap of 4.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while DIGISPICE.NS trades at ₹20.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas DIGISPICE.NS's P/E ratio is 21.91. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DIGISPICE.NS's ROE of +0.09%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to DIGISPICE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DIGISPICE.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, DIGISPICE.BO has a market cap of 4.8B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while DIGISPICE.BO trades at ₹20.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas DIGISPICE.BO's P/E ratio is 22.20. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to DIGISPICE.BO's ROE of +0.09%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to DIGISPICE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check DIGISPICE.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, INSPIRISYS.BO has a market cap of 4.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while INSPIRISYS.BO trades at ₹113.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas INSPIRISYS.BO's P/E ratio is 11.61. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INSPIRISYS.BO's ROE of +0.57%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to INSPIRISYS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INSPIRISYS.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, INSPIRISYS.NS has a market cap of 4.4B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while INSPIRISYS.NS trades at ₹111.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas INSPIRISYS.NS's P/E ratio is 11.32. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to INSPIRISYS.NS's ROE of +0.57%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to INSPIRISYS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check INSPIRISYS.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, SIGMA.BO has a market cap of 4.3B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while SIGMA.BO trades at ₹41.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas SIGMA.BO's P/E ratio is 17.67. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SIGMA.BO's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to SIGMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SIGMA.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, CYBERTECH.NS has a market cap of 4.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while CYBERTECH.NS trades at ₹136.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas CYBERTECH.NS's P/E ratio is 13.97. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CYBERTECH.NS's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CYBERTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CYBERTECH.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, CYBERTECH.BO has a market cap of 4.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while CYBERTECH.BO trades at ₹136.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas CYBERTECH.BO's P/E ratio is 13.96. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to CYBERTECH.BO's ROE of +0.14%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to CYBERTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check CYBERTECH.BO's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, SIGMA.NS has a market cap of 4.2B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while SIGMA.NS trades at ₹40.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas SIGMA.NS's P/E ratio is 17.52. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to SIGMA.NS's ROE of +0.40%. Regarding short-term risk, EXPLEOSOL.BO is more volatile compared to SIGMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check SIGMA.NS's competition here

EXPLEOSOL.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXPLEOSOL.BO stands at 12.2B. In comparison, XTGLOBAL.BO has a market cap of 3.9B. Regarding current trading prices, EXPLEOSOL.BO is priced at ₹783.95, while XTGLOBAL.BO trades at ₹28.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXPLEOSOL.BO currently has a P/E ratio of 9.81, whereas XTGLOBAL.BO's P/E ratio is 34.46. In terms of profitability, EXPLEOSOL.BO's ROE is +0.17%, compared to XTGLOBAL.BO's ROE of +0.07%. Regarding short-term risk, EXPLEOSOL.BO is less volatile compared to XTGLOBAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EXPLEOSOL.BO.Check XTGLOBAL.BO's competition here